Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2025
0mins
Should l Buy ORGO?
Source: Benzinga
U.S. Stock Market Update: U.S. stock futures rose, particularly the Nasdaq which gained around 100 points, while Simulations Plus, Inc. saw a significant drop of 6.3% in pre-market trading after disappointing quarterly sales and a lowered EPS guidance for FY2025.
Other Stocks Performance: Several other stocks experienced declines in pre-market trading, including Presidio Property Trust (-29.9%), MiNK Therapeutics (-27.5%), and Organogenesis Holdings (-26.7%), following downgrades and negative earnings reports.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORGO
Wall Street analysts forecast ORGO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.290
Low
9.00
Averages
9.00
High
9.00
Current: 2.290
Low
9.00
Averages
9.00
High
9.00
About ORGO
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against Organogenesis Holdings Inc., suggesting that the company and its executives may have engaged in unlawful business practices, prompting investors to reach out for more information.
- Impact of Healthcare Policy: On December 26, 2025, the Centers for Medicare & Medicaid Services announced the withdrawal of final Local Coverage Determinations related to skin substitute grafts, leading to increased competition from over 300 market participants for Organogenesis.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a renowned firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years, highlighting its expertise and influence in such cases.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings Inc.
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Organogenesis Holdings Inc. for potential securities fraud and other unlawful business practices, aiming to protect investor rights and possibly lead to a class action lawsuit.
- Impact of Policy Changes: On December 26, 2025, the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, increasing competitive pressure on Organogenesis from over 300 market participants.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities, antitrust, and corporate class litigation, having recovered millions of dollars for victims of securities fraud over its 85-year history, showcasing its expertise and influence in the field.
See More
Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%
- Securities Fraud Investigation: Pomerantz LLP is investigating Organogenesis Holdings Inc. for potential securities fraud involving the company and its executives, which could undermine investor confidence and lead to stock volatility.
- Increased Market Competition: The withdrawal of final Local Coverage Determinations by the Centers for Medicare & Medicaid Services means Organogenesis will face competition from over 300 market participants, potentially impacting its market share and profitability.
- Stock Price Reaction: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, reflecting market concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, may lead to legal liabilities for Organogenesis, further affecting its financial health and investor trust.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Organogenesis Submits BLA for ReNu, Expected Completion in 2026
- BLA Submission Initiated: Organogenesis has begun the submission of a Biologics License Application for ReNu to the FDA, expected to be completed in the first half of 2026, which will provide a new treatment option for knee arthritis patients, particularly those classified as severe.
- Clinical Trial Support: The application for ReNu is backed by three large randomized controlled trials enrolling over 1,300 patients, demonstrating its efficacy in treating knee osteoarthritis and further solidifying its market potential.
- Strong Market Demand: Currently, approximately 31.1 million Americans are affected by knee osteoarthritis, with projections rising to 34.4 million by 2027, and the launch of ReNu will fill a gap in non-surgical biologic therapies to meet the growing patient needs.
- Improved Financial Performance: Organogenesis reported a net income of $21.6 million in Q3 2025, up from $12.3 million in the same quarter last year, indicating strong performance in the biologics market and future growth potential.
See More
Organogenesis Initiates BLA Submission for ReNu, Targeting Knee Arthritis Treatment
- Significant Milestone: Organogenesis has officially initiated the rolling submission of a Biologics License Application (BLA) for ReNu, with plans to complete the final modules in the first half of 2026, marking a crucial advancement in knee arthritis treatment.
- Market Potential: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, and approval of ReNu would provide the first non-surgical biologic therapy for these patients, addressing a critical market need.
- Clinical Research Foundation: ReNu has been studied in three large randomized controlled trials involving over 1,300 patients and received FDA RMAT designation in 2021, demonstrating its potential and safety in clinical applications.
- Strategic Implications: This application not only showcases Organogenesis's innovative capabilities in regenerative medicine but also has the potential to transform treatment options for knee arthritis patients, thereby enhancing the company's competitive position in the market.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings
- Securities Fraud Investigation: Pomerantz LLP is investigating claims of securities fraud against Organogenesis Holdings Inc., suggesting that the company and its executives may have engaged in unlawful business practices, prompting investors to reach out for more information.
- Impact of Healthcare Policy: On December 26, 2025, the Centers for Medicare & Medicaid Services announced the withdrawal of final Local Coverage Determinations related to skin substitute grafts, leading to increased competition from over 300 market participants for Organogenesis.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a renowned firm in corporate and securities class litigation, having fought for the rights of victims of securities fraud for over 85 years, highlighting its expertise and influence in such cases.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against Organogenesis Holdings Inc.
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Organogenesis Holdings Inc. for potential securities fraud and other unlawful business practices, aiming to protect investor rights and possibly lead to a class action lawsuit.
- Impact of Policy Changes: On December 26, 2025, the Centers for Medicare & Medicaid Services withdrew final Local Coverage Determinations related to skin substitute grafts, increasing competitive pressure on Organogenesis from over 300 market participants.
- Stock Price Decline: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, indicating market concerns regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP is a prominent law firm specializing in securities, antitrust, and corporate class litigation, having recovered millions of dollars for victims of securities fraud over its 85-year history, showcasing its expertise and influence in the field.
See More
Organogenesis Faces Securities Fraud Investigation, Stock Drops 10.14%
- Securities Fraud Investigation: Pomerantz LLP is investigating Organogenesis Holdings Inc. for potential securities fraud involving the company and its executives, which could undermine investor confidence and lead to stock volatility.
- Increased Market Competition: The withdrawal of final Local Coverage Determinations by the Centers for Medicare & Medicaid Services means Organogenesis will face competition from over 300 market participants, potentially impacting its market share and profitability.
- Stock Price Reaction: Following this news, Organogenesis's stock price fell by $0.59, or 10.14%, closing at $5.28 per share on December 30, 2025, reflecting market concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, may lead to legal liabilities for Organogenesis, further affecting its financial health and investor trust.
See More
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%
- Reverse Stock Split Announcement: Aptevo Therapeutics has announced a 1-for-18 reverse stock split effective December 29, converting every 18 shares into one, which has led to a significant 38.4% drop in share price to $0.57, indicating a negative market reaction despite prior shareholder approval in July.
- Severe Market Reaction: Following the reverse stock split announcement, Aptevo's shares plummeted sharply during Friday's session, reflecting investor concerns about the company's future prospects, which could adversely affect its financing capabilities and market confidence.
- Shareholder Approval Context: The final ratio for the reverse split was approved by the board in mid-December, despite having received shareholder support at the July annual meeting, yet the market's response raises questions about the company's governance and strategic direction.
- Industry Impact: The sharp decline in Aptevo's stock price may affect its competitive position in the biopharmaceutical sector, particularly regarding financing and partnership opportunities, as investors may reassess its investment value.
See More
Organogenesis Submits BLA for ReNu, Expected Completion in 2026
- BLA Submission Initiated: Organogenesis has begun the submission of a Biologics License Application for ReNu to the FDA, expected to be completed in the first half of 2026, which will provide a new treatment option for knee arthritis patients, particularly those classified as severe.
- Clinical Trial Support: The application for ReNu is backed by three large randomized controlled trials enrolling over 1,300 patients, demonstrating its efficacy in treating knee osteoarthritis and further solidifying its market potential.
- Strong Market Demand: Currently, approximately 31.1 million Americans are affected by knee osteoarthritis, with projections rising to 34.4 million by 2027, and the launch of ReNu will fill a gap in non-surgical biologic therapies to meet the growing patient needs.
- Improved Financial Performance: Organogenesis reported a net income of $21.6 million in Q3 2025, up from $12.3 million in the same quarter last year, indicating strong performance in the biologics market and future growth potential.
See More
Organogenesis Initiates BLA Submission for ReNu, Targeting Knee Arthritis Treatment
- Significant Milestone: Organogenesis has officially initiated the rolling submission of a Biologics License Application (BLA) for ReNu, with plans to complete the final modules in the first half of 2026, marking a crucial advancement in knee arthritis treatment.
- Market Potential: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, and approval of ReNu would provide the first non-surgical biologic therapy for these patients, addressing a critical market need.
- Clinical Research Foundation: ReNu has been studied in three large randomized controlled trials involving over 1,300 patients and received FDA RMAT designation in 2021, demonstrating its potential and safety in clinical applications.
- Strategic Implications: This application not only showcases Organogenesis's innovative capabilities in regenerative medicine but also has the potential to transform treatment options for knee arthritis patients, thereby enhancing the company's competitive position in the market.
See More
